Septerna ends Phase 1 trial for hypoparathyroidism drug; Sanofi’s Merilog is approved

Plus, news about Basilea, TME Pharma and Perceive Biotherapeutics: Septerna stops work on Phase 1: The newly public biotech ended a healthy volunteer trial for SEP-786, its hypoparathyroidism ...

Related Posts

Trump’s picks for NIH, CMS say they’ll unload industry ...

Feb 20, 2025  0

Roche heads to FDA with Gazyva results in a form of lupus

Feb 9, 2025  0

Travere plans to seek expanded label for kidney drug

Feb 11, 2025  0

Comments

Name

Email

Comment

Post Comment